1. Academic Validation
  2. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor

G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor

  • Circulation. 2005 Apr 12;111(14):1806-13. doi: 10.1161/01.CIR.0000160867.23556.7D.
Evi Kostenis 1 Graeme Milligan Arthur Christopoulos Carlos F Sanchez-Ferrer Silvia Heringer-Walther Patrick M Sexton Florian Gembardt Elaine Kellett Lene Martini Patrick Vanderheyden Heinz-Peter Schultheiss Thomas Walther
Affiliations

Affiliation

  • 1 7TM Pharma, Hoersholm, Denmark.
Abstract

Background: We previously identified the G-protein-coupled receptor Mas, encoded by the Mas proto-oncogene, as an endogenous receptor for the heptapeptide angiotensin-(1-7); however, the receptor is also suggested to be involved in actions of angiotensin II. We therefore tested whether this could be mediated indirectly through an interaction with the angiotensin II type 1 receptor, AT1.

Methods and results: In transfected mammalian cells, Mas was not activated by angiotensin II; however, AT1 receptor-mediated, angiotensin II-induced production of inositol phosphates and mobilization of intracellular Ca2+ was diminished by 50% after coexpression of Mas, despite a concomitant increase in angiotensin II binding capacity. Mas and the AT1 Receptor formed a constitutive hetero-oligomeric complex that was unaffected by the presence of agonists or antagonists of the 2 receptors. In vivo, Mas acts as an antagonist of the AT1 receptor; mice lacking the Mas gene show enhanced angiotensin II-mediated vasoconstriction in mesenteric microvessels.

Conclusions: These results demonstrate that Mas can hetero-oligomerize with the AT1 Receptor and by so doing inhibit the actions of angiotensin II. This is a novel demonstration that a G-protein-coupled receptor acts as a physiological antagonist of a previously characterized receptor. Consequently, the AT1-Mas complex could be of great importance as a target for pharmacological intervention in cardiovascular diseases.

Figures